Masked Clowns Strike Fear in Israel

Israeli police are on the lookout for teenagers in clown masks after a group of them struck fear among Israelis. (AFP)
Israeli police are on the lookout for teenagers in clown masks after a group of them struck fear among Israelis. (AFP)
TT

Masked Clowns Strike Fear in Israel

Israeli police are on the lookout for teenagers in clown masks after a group of them struck fear among Israelis. (AFP)
Israeli police are on the lookout for teenagers in clown masks after a group of them struck fear among Israelis. (AFP)

Israeli police are on the lookout for teenagers in clown masks after a group of them struck fear among Israelis.

Police spokesperson Micky Rosenfeld told AFP: “Police operations are continuing in different areas to protect public places and prevent further incidents.”

He noted that many of them were already detained, revealing that about 12 youngsters, including two 14-year-olds, were arrested over the past few days.

A previous police statement said that "dozens of youngsters from all parts of the country were detained for questioning after putting masks on their faces in order to sow fear and panic among the public".

Rosenfeld said that they sought only to frighten people, not to harm them. "There haven't been any attacks. It's just been people dressed up and walking around with fake axes and fake knives," he added.

The spokesperson has, however, warned that such pranks could go horribly wrong.

"There is a concern that such pranks will be interpreted as a real threat and will cause harm to the youngsters," he said. "It is absolutely forbidden for people to take the law into their own hands and harm wearers of masks."

Local media said that a victim of an incident in the southern city of Beersheba last week stabbed his tormentor, causing moderate injuries. Police did not confirm the reports.

Media have suggested a link between the phenomenon and the recent film based on Stephen King's novel, “It”, featuring an evil clown who preys on teenagers. The Israeli police advised members of the public confronted by a masked person to ignore them.

"In these situations, move away from the scene and report it to the police as soon as possible," the official police Facebook page says.



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”